https://scholars.lib.ntu.edu.tw/handle/123456789/638447
標題: | Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors | 作者: | Bauer, Todd M Santoro, Armando CHIA-CHI LIN Garrido-Laguna, Ignacio Joerger, Markus Greil, Richard Spreafico, Anna Yau, Thomas Goebeler, Maria-Elisabeth Hütter-Krönke, Marie Luise Perotti, Antonella Juif, Pierre-Eric Lu, Darlene Barys, Louise Cremasco, Viviana Pelletier, Marc Evans, Helen Fabre, Claire Doi, Toshikiko |
關鍵字: | Drug Therapy, Combination; Immunotherapy; Non-Small Cell Lung Cancer; Programmed Cell Death 1 Receptor; Therapies, Investigational | 公開日期: | 29-十一月-2023 | 卷: | 11 | 期: | 11 | 來源出版物: | Journal for immunotherapy of cancer | 摘要: | NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638447 | ISSN: | 2051-1426 | DOI: | 10.1136/jitc-2023-007353 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。